Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Chronic Lymphocytic Leukemia
Related studies linked through entity extraction aliases.
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
- Status
- COMPLETED
- Phase
- PHASE2
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Status
- WITHDRAWN
- Phase
- N/A
Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients
- Status
- UNKNOWN
- Phase
- PHASE1
Personalized Multi-peptide Vaccination in CLL Patients
- Status
- COMPLETED
- Phase
- PHASE1
huCART19-IL18 in CD19+ Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of FCN-338 in Patients With Chronic CLL/SLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
- Status
- RECRUITING
- Phase
- PHASE2
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
SARS-CoV-2 Donor-Recipient Immunity Transfer
- Status
- COMPLETED
- Phase
- N/A
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
- Status
- WITHDRAWN
- Phase
- PHASE2
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
- Status
- RECRUITING
- Phase
- NA
Early Intervention With Acalabrutinib in Patients With High Risk CLL
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients
- Status
- UNKNOWN
- Phase
- NA
FT819 in Subjects With B-cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- N/A